CDNA Maintained by Canaccord Genuity -- Price Target Raised to $80

gurufocus.com · 2026-10-19

CareDx (CDNA) Analyst Rating Update - Overvalued Yet Promising On October 3, 2023, CareDx (CDNA) has received a maintained Buy rating from Canaccord Genuity.

TickrTrends take: Canaccord Genuity raised its price target for CDNA to $80, reflecting analyst confidence in the company's prospects within the Healthcare sector. However, TickrTrends currently indicates that CDNA trades at an overvalued level relative to its fundamentals, suggesting the analyst's target may not align with current valuation metrics. Investors focused on valuation should monitor whether CDNA's financial performance and growth rates can justify closing the gap between the new price target and the stock's current trading levels.

Read the full story at gurufocus.com →